• Activity INFORMATION

  Overview

  In a podcast style discussion, Mike Corvino, PharmD and Cole Swanson, PharmD examine the updated 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.  The global economic burden of heart failure is estimated to be $108 billion annually. The U.S accounts for 28.4% of this cost. There have been a number of landmark clinical trials leading to practice changing recommendations in recent years, aimed at reducing morbidity and mortality in patients with heart failure. This guideline evaluates this new data and applies it to the recommendations. Pharmacists and nurses regularly encounter patients with heart failure. It is important that pharmacists and nurses understand the appropriate use of the relevant medications and know how to identify patients who could benefit from them. This session seeks to explore these topics, focusing on how this information can best be incorporated into daily medical practice.

  Access the original podcast here.

  
  

  Handouts

  Financial Support By

  PharmCon

• Learning OBJECTIVES

  Pharmacist

  Recognize the place in therapy of SGLT-2 inhibitors in the treatment of HFrEF

  Identify and address cost-prohibitive factors that may prevent incorporating the recommended changes

  Identify updated recommendations for the treatment of HFrEF and HFpEF

  Review specific landmark clinical trials that resulted in the updated recommendations

  Nurse

  Review specific landmark clinical trials that resulted in the updated recommendations

  Recognize the place in therapy of SGLT-2 inhibitors in the treatment of HFrEF

  Identify and address cost-prohibitive factors that may prevent incorporating the recommended changes

  Identify updated recommendations for the treatment of HFrEF and HFpEF

• Activity ACCREDITATION

  Activity Type

  Knowledge

  CE Broker

  20-915524

  Universal Activity Number

  Pharmacist 0798-0000-22-166-H01-P
  Nurse 0798-0000-22-166-H01-N
  

  PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

  PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

  In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

• Activity INSTRUCTION

  Faculty

  Coleman  Swanson, PharmD, CDCES Clinical Pharmacist - Neurology, MUSC Specialty Pharmacy Department

  Michael  Corvino, PharmD, BCPS, BCACP, CDCES Clinical Pharmacist, Fetter Health Care Network

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).